NCT02670746View on ClinicalTrials.gov

A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer

TerminatedOBSERVATIONAL
Enrollment

44

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions
Pancreatic Neoplasms
Trial Locations (18)

6815 A

Rijnstate Ziekenhuis, Arnhem

4818 CK

Amphia ziekenhuis, Breda

2545 CH

Gelderse Vallei, Ede

HagaZiekenhuis, The Hague

5707 HA

Elkerliek Ziekenhuis, Helmond

5504 DB

Maxima Medisch Centrum, Veldhoven

1034 CS

BovenIJ Ziekenhuis, Amsterdam

1105 AZ

Academic Medical Centre, Amsterdam

2035 RC

Spaarne Gasthuis, Haarlem

1213XZ

Tergooi, Hilversum

8025 AB

Isala, Zwolle

8841 PW

Ziekenhuis de Tjongerschans, Heerenveen

8601 ZK

Antonius Ziekenhuis Sneek, Sneek

3328 AT

Albert Schweitzer Ziekenhuis, Dordrecht

2333 ZA

LUMC, Leiden

4535 PA

Zorgsaam Zeeuws -Vlaanderen, Terneuzen

9728 NT

Martini Ziekenhuis, Groningen

3584 CX

UMC Utrecht, Utrecht

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02670746 - A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer | Biotech Hunter | Biotech Hunter